 |
|
|
|
|
| |
 |
|
|
| |
Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies. |
|
| |
|
|
| |
| |
|
| |
|
|
Histogenics Corporation
100 Hospital Road
Malden, MA 02148
Phone: 781-321-8160
Fax: 781-321-9763
|
|
| |
| |
Histogenics Corporation expertise and focus is on repairing articular cartilage damage utilizing advancements in cell biology, tissue culture, engineering, and materials science to affect tissue repair. The Company’s technology is based on the work of Dr. Shuichi Mizuno of Brigham and Women’s Hospital, a Harvard Medical School affiliated teaching hospital, in collaboration with Takagi Industrial Co., Ltd., a Japanese firm specializing in computer-controlled machinery.
Articular cartilage lines the articulating joints of the body and serves to provide a smooth and low friction surface. This cartilage can be injured as a result of trauma or general wear and tear. When injured, a lesion forms on the surface of a joint leading to pain and reduced function. These lesions are not naturally repaired by the body and can progress to osteoarthritis. Once osteoarthritis has developed, the gold standard therapy is joint replacement. Joint replacement is not, however, generally practical until the patient reaches the age of 50 or so.
Histogenics’ NeoCart System enables a surgeon to extract a sample of a patient’s native chondrocytes, culture them and then re-implant them into a lesion using a proprietary collagen matrix and glue. This System also includes the biopsy and implantation instrument set. In addition, the company also plans to test a single step procedure that involves use of the matrix without the addition of any cells, as well as a single step procedure that uses the matrix with growth factors but no extracted cells.
Histogenics has assembled a portfolio of patents that protect the Company’s investment in technology and its position in the tissue engineering field. The Company holds 15 applications on the structure and function of NeoCart and related products. It holds a series of 3 issued US patents and 12 applications on the processor. In addition, it licenses a pressure algorithm series which thus far includes one US patent and eight additional applications from Stanford University. |
|
| |
|
| Millennia Team |
Pat Fortune, Ph.D.,
Brad Callow
|
|
| Investment Date |
July 14, 2006 |
|
| Visit the Website |
http://www.histogenics.com |
|
| Related News |
American Way - September 1, 2009
Cultivating Second Chances
Waltham, MA - September 2, 2008
Histogenics Secures $9 Million in Second Round of Financing
Waltham, MA - May 30, 2008
Histogenics Appoints Ken Andrews President and CEO
Waltham, MA - September 26, 2007
Histogenics NeoCart Cartilage Therapy Found Promising in OHSU Study
Waltham, MA - May 21, 2007
Histogenics Names Bernitz President and Chief Executive Officer
Portland, OR - November 28, 2006
OHSU Doctors Test Disc to Repair Knee Cartilage Damage
Boston, MA - August 22, 2006
Boston Millennia Partners Invests in Histogenics Corporation
|
|
|
|
|
|
|
|
|
|
